What Dacryoserum Treats: Main Uses and Benefits

Supportive Management of Ocular Discomfort

Dacryoserum is primarily used as an ocular lavage solution for the management of conjunctival irritation. The solution is authorized for this indication and is considered a supportive treatment. It is applied across domains where additional symptomatic support is needed.

Symptom Relief and Hygiene

The medicine is used to address symptomatic discomfort related to foreign body sensation and the resulting ocular discomfort caused by external factors. Its therapeutic benefit lies in performing an ocular lavage, cleansing the eye surface by rinsing away irritant particles and debris, which contributes to the easing of the resulting symptoms. The solution provides supportive relief for common symptoms related to mild, localized irritation, specifically targeting the burning sensation, itching (pruritus), and secondary redness of the conjunctiva. This medicine can assist with maintaining comfort and easing the overall symptom load during episodes of symptomatic discomfort, and is relevant for supporting a clean eye surface in conditions such as non-severe infectious conjunctivitis or blepharitis.

Quick Facts: Therapeutic Focus

Regulatory References

1. Haute Autorité de Santé (HAS) summary

Dacryoserum, an ophthalmic solution containing Boric Acid and Sodium Tetraborate, has officially documented population eligibility rules that define who can and cannot use the medicine.

Contraindications (Must Not Use) Use is absolutely contraindicated in any individual with a known hypersensitivity or allergy to the active ingredients (Boric Acid, Sodium Tetraborate) or any other constituent of the solution.

Age-Based Eligibility Use is generally permitted for adult and adolescent populations under standard labeled conditions. However, the medicine's use in the pediatric population (children) is not established, as official regulatory documents state that no clinical data is available for this age group.

Conditional and Restricted Use For individuals who are pregnant or breastfeeding, the medicine must be used with prudence according to regulatory requirements. Additionally, patients who wear soft hydrophilic contact lenses are advised to avoid using formulations of Dacryoserum that contain a preservative.

Interactions with other medicines and products

Official regulatory information for Dacryoserum (borax and boric acid ophthalmic solution) indicates a highly limited interaction profile, primarily due to its topical route of administration and negligible systemic absorption.

Documented Interaction

This constraint is a procedural requirement designed to prevent the eyewash from immediately diluting or flushing out subsequently applied medications, which could reduce their intended effect. This rule applies universally to co-administration with other treatments applied to the eye.

Undocumented/Negligible Interactions

Official government labels confirm the absence of several categories of potential interactions:

• Pharmacokinetic Interactions: No clinically relevant interactions are documented for the drug with cytochrome P450 enzymes or drug transporters, as systemic exposure is insignificant.
• Food, Alcohol, or Herbal Products: No specific interactions with food, alcohol, or herbal products are documented, consistent with the topical use of the product.

No specific medicinal products by brand or generic name are explicitly listed as strictly contraindicated for co-administration. The absence of systemic exposure means that interaction risk is confined to the local area and administration sequence.

Dacryoserum, containing borax and boric acid, exerts its primary pharmacodynamic actions topically at the ocular surface. The borate components function as an antiseptic agent by disrupting microbial cell wall integrity and inhibiting key enzyme systems necessary for bacterial proliferation. This interaction leads to the cellular demise of targeted microorganisms. Additionally, the formulation possesses a mild astringent action mediated by the borate ion. Astringents precipitate proteins on the cell surface, leading to a superficial, non-specific binding and cross-linking of proteins within the epithelial layer of the conjunctiva. This protein coagulation produces a localized micro-layer, which systemically modulates fluid dynamics by reducing passive fluid extravasation across the mucosal surface. The system-level physiological consequence is a localized tissue surface compaction and a modification of the superficial tissue microenvironment.

The administration of Dacryoserum is officially specified as a topical regimen for ocular lavage (eye washing). The medicine is supplied as a pre-prepared solution in a single-dose container.

Administration Protocol

Procedural Constraints and Timing

Official instructions define several procedural conditions necessary for proper use. Prior to administration, contact lenses must be removed. The wash is performed using a direct jet from the container, and care must be taken to prevent the container tip from touching the eye surface. To maintain sterility and proper dosing, the single-dose container must be used immediately upon opening and discarded immediately after use; reuse of any part of the solution is not permitted. If the patient is using other ophthalmic medications, an interval of 15 minutes must be observed between the Dacryoserum wash and the instillation of the subsequent product. Regarding specific patient groups, official regulatory documentation states that no data is available concerning use in the pediatric population.

Research Evidence / Overview of studies for Dacryoserum

Evidence for use in Conjunctival Irritation

Research has examined Dacryoserum in the context of general eye discomfort and irritation. Studies were primarily applied in research contexts involving fluctuating or unstable symptoms related to the eye's surface. These studies explored how symptoms like redness or mild tearing change over time following the use of an eye wash. Outcomes relevant in evidence describing how symptoms are measured focused on patient-reported outcomes describing perceived discomfort and outcomes linked to inflammatory or irritative states.

Findings describe patterns observed in the studies where individuals reported descriptions of patterns related to temporary changes in outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level. Research highlights changes measured during the study period, particularly in the short-term symptom patterns. However, comparative evidence is lacking to fully understand how these patterns compare against other options available for eye irritation.

Evidence for use in Non-Severe Infectious Conjunctivitis

This part will outline the structural evidence related to the supportive role of Dacryoserum as a local antiseptic and mild astringent in cases of non-severe infectious conjunctivitis, describing which outcomes were measured in these specific contexts.

Dacryoserum was studied for its supportive role in conditions associated with acute or disruptive episodes, specifically non-severe infectious conjunctivitis. Research examined its application in situations where patients presented with cycles of stability and flare-ups, focusing on outcomes capturing phases of heightened symptom activity. Studies monitored outcomes related to physical discomfort and outcomes linked to inflammatory or irritative states.

Studies report how symptoms evolved in the observed populations during the short-term course of the condition. Data show patterns related to descriptions of patterns related to temporary shifts in perceived discomfort and outcomes describing episodic or acute changes. The role of Dacryoserum was studied in the context of supportive care, but research has primarily observed its use rather than determining a specific contribution to infection resolution. Certainty remains low regarding its stand-alone application against the underlying infectious cause.

Long-term Studies and Follow-up

Research has explored the effects of Dacryoserum over defined time intervals, but findings from long-term effects are not fully established. Most studies exploring symptom evolution have focused on outcomes measured over hours, days, or a few weeks. This means that follow-up durations were limited.

There is limited information for long-term outcomes when Dacryoserum is observed in use repeatedly over months or years, for conditions characterized by fluctuating or episodic manifestations.

Evidence in Special Populations

Dacryoserum was evaluated in studies involving different age groups, including children, as part of research exploring short-term symptom changes. However, data for certain groups remain insufficient. For instance, there is limited information from structured research regarding its use during pregnancy and breastfeeding or in patients with significant co-morbid conditions.

What is Still Uncertain about Dacryoserum

The overall evidence landscape has limitations in its structure that restrict the understanding of symptom patterns. Comparative evidence is lacking to fully understand how Dacryoserum compares against other available ophthalmic wash solutions. Furthermore, the available data are generally derived from studies with modest sample sizes and focused on temporary physiological imbalance. Research data remain uncertain for special populations and conditions involving periods of heightened symptoms.

Key Studies & References Clinical Review of Antiseptic Eye Washes for Non-Severe Ophthalmic Irritation (Focus on Traditional Usage and Observation)

Common questions about Dacryoserum (FAQ)

Q: What is the main active ingredient in Dacryoserum and how does it work?

The main active ingredient in Dacryoserum is boric acid. Boric acid works as a mild antiseptic and astringent. As an antiseptic, it helps to slow or stop the growth of microorganisms on the surface of the eye. As an astringent, it helps to tighten and dry the affected tissue, which can reduce minor irritation and discharge associated with certain mild eye and eyelid conditions.

Q: What is Dacryoserum used for?

Dacryoserum is primarily used for ocular rinsing and as a mild antiseptic for the eyes and surrounding tissues. It is commonly recommended for the complementary treatment of minor, non-infectious conditions affecting the eyes and eyelids, such as:

• Mild conjunctival irritation
• Eyelid irritation (blepharitis)
• Relief of dryness or discomfort due to minor irritants
• Routine cleansing of the eye area

It is important to note that Dacryoserum is intended only for mild, surface-level conditions and should not replace treatment for serious eye infections or injuries.

Q: How do I apply Dacryoserum?

Dacryoserum is designed for ocular external use only. You should follow these general steps, or the specific instructions provided by your pharmacist or prescribing healthcare professional:

1. Preparation: Wash your hands thoroughly before handling the single-dose container.
2. Application: Gently tilt your head back or look up. Apply a few drops directly to the surface of the affected eye(s) or use the solution to rinse the eye or eyelid area.
3. Wiping: Use a clean, sterile compress or cotton ball to gently wipe the area if necessary, moving from the inside corner of the eye toward the outside.
4. Disposal: The contents of a single-dose container must be used immediately after opening. Discard any unused portion to ensure sterility. Do not save or reuse an open single-dose vial.

Always ensure the tip of the container does not touch your eye or any other surface to prevent contamination.

Q: Are there any side effects associated with Dacryoserum?

Side effects with Dacryoserum are rare when used as directed for external ocular rinsing. However, some people may experience mild, temporary irritation or a stinging sensation immediately after application.

Discontinue use and consult a healthcare professional if you experience:

• Severe stinging or burning sensation
• Worsening redness or swelling
• Any signs of an allergic reaction (e.g., rash, itching)
• The condition does not improve within a few days of use

Because of the boric acid content, Dacryoserum is not recommended for prolonged or extensive use, especially in infants or children, unless specifically advised by a medical professional.

Q: Can Dacryoserum be used by contact lens wearers?

It is generally recommended that contact lenses be removed before using Dacryoserum. Some ingredients in eye solutions can interact with soft contact lenses or cause them to become discolored or damaged. Once you have used the solution, wait for the amount of time recommended by your eye care professional—typically at least 15 minutes—before reinserting your contact lenses. If you are unsure, consult your eye care specialist.

Q: How should Dacryoserum be stored?

Dacryoserum must be stored according to the manufacturer's instructions to maintain its stability and sterility:

• Temperature: Store at room temperature, typically below 25°C (77°F), away from excessive heat or freezing.
• Container: Keep the single-dose containers in their original sealed pouch or box until ready to use.
• Safety: Keep Dacryoserum and all medications out of the reach and sight of children.

Official Storage and Disposal Requirements

This section outlines the regulatory requirements for storing, handling, and disposing of Dacryoserum, based strictly on government-issued prescribing information.